| ||||
| ||||
| Viragen and the U.K.'s Cancer Research Campaign Collaborate To Develop a Cancer Vaccine |
| Viragen, Inc. , announced today
that its subsidiary, Viragen Ltd., in collaboration with the University of
Nottingham and Cancer Research Campaign Technology has signed an agreement
to develop a new cancer vaccine therapy for the treatment of several
indications, including breast, ovarian and colorectal cancers.[PR Newswire] |
| [B] FULL/ Viragen, UK university to develop cancer vaccine therapy |
| New York--Jul 27--Viragen Inc.'s
Viragen Scotland unit will collaborate with the University of Nottingham
and Cancer Research Campaign Technology, a unit of Cancer Research
Campaign, a U.K. charity, to develop a new cancer vaccine therapy for the
treatment of breast, ovarian and colorectal cancers.[Bridge Information Systems,
Inc.] |
| Genetronics Announces Return of Rights From Ethicon Endo-Surgery |
| Genetronics Biomedical Limited,
San Diego, announced today that Ethicon Endo-Surgery, Inc., a Johnson
& Johnson company, has elected to exercise its discretionary right to
terminate without cause the Licensing and Development Agreement and the
Supply Agreement it entered into with Genetronics, Inc.[Canada
NewsWire] |
| [B] FULL/ Tularik Inc. begins Phase I/II T67 carcinoma trial |
| New York--July 27-- Tularik Inc.
has initiated phase I/II efficacy study for its anti-cancer drug
candidate, T67, in patients with hepatocellular carcinoma . Many tumors,
which have become resistant to other anti-cancer drugs, were found to be
vulnerable to T67 in pre-clinical experiments.[Bridge Information Systems,
Inc.] |
| SpectraSCIENCE Receives ISO 9001 Certification |
| SpectraSCIENCE, Inc. announced
today that it received ISO 9001 Certification from its European Notified
Body.[Business
Wire] |
| Tularik Announces the Initiation of an Efficacy Study in Patients With Hepatocellular Carcinoma |
| Tularik Inc. today announced the
initiation of a phase I/II efficacy study for its anti-cancer drug
candidate, T67, in patients with hepatocellular carcinoma .[PR Newswire] |
| Nature Immunology Reports Antigenics' Sequencing of Heat Shock Protein Receptor A Critical Switch in Regulating the Immune System |
| A receptor that controls the
ability of the body's immune system to combat disease has been discovered.
The receptor, CD91, has been sequenced and identified as a heat shock
protein receptor by Pramod K Srivastava, Ph.D.[PR Newswire] |
| THE HINDU/ Milestone in colon cancer treatment |
| A long-awaited study suggests that
a class of asprin-like compounds could help prevent colon
cancer.[All Material Subject to
Copyright] |
| SMITHKLINE BEECHAM/ Coulter Pharmaceutical and SmithKline Beecham expand proprietary position with second U.S. patent grant this year |
| Coulter Pharmaceutical and
SmithKline Beecham today announced that the U.S. Patent and Trademark
Office has issued another patent relating to CD20 antibody therapy for the
treatment of lymphoma.[M2 Communications,
Inc.] |
| [B] FULL/ Johnson & Johnson unit ends license pact with Genetronics |
| New York--Jul 26--Johnson &
Johnson's unit Ethicon Endo-Surgery Inc. terminated a licensing,
development and supply agreement it had entered into with Genetronics
Inc.[Bridge Information Systems,
Inc.] |
|
